Preclinical studies supporting pediatric drug development : Evaluate pediatric safety profile and developmental toxicity issues
Evaluation of pharmaceutical agents for children is now conducted earlier in the drug development process. An important consideration for this pediatric use is how to assess and support its safety.
NemoClinics supplies a comprehensive in vivo screening methodology for new candidate drugs and paediatric indications. Our sensitive and robust tests are particularly effective to investigate toxicity of new paediatric medications in newborn or juvenile rats or mice. This methodology is applicable either at the lead optimization stage or later to address specific phenotyping questions, i.e. in parallel to clinical trial.
NemoClinics experts and co-founders bring together their pediatric clinical research experience and a significant drug development background to support your Paediatric Investigation Plans (PIP) strategies.
For more information, please contact us